Reasons and treatment methods for tumors to increase during taking regorafenib (Belvango)

1. Overview of the mechanism of action of regorafenib

Regorafenib (Regorafenib) is an oral multi-target tyrosine kinase inhibitor (TKI) that can simultaneously inhibit VEGFR, PDGFR, FGFR, KIT, RET and other signaling pathways. By blocking tumor angiogenesis, tumor cell proliferation, and signaling in the tumor microenvironment, regorafenib is widely used to treat a variety of malignant tumors such as advanced colorectal cancer (mCRC), gastrointestinal stromal tumor (GIST), and hepatocellular carcinoma (HCC). In clinical practice, regorafenib is often used as a rescue drug after standard treatment failure, which can delay disease progression and improve patient survival prognosis.

However, some patients experience an increase in tumor size while taking regorafenib, which confuses patients and doctors. In fact, multiple mechanisms are involved behind this phenomenon and require comprehensive evaluation.

2. Possible causes of tumor growth

1.The progression of the disease itself

Regorafenib is mainly used for patients with advanced disease who have failed multiple lines of treatment. The tumors of these patients are usually highly aggressive and drug-resistant. Even while taking regorafenib, the tumor may continue to grow rapidly due to genetic mutations or clonal evolution, resulting in increased tumor size on imaging studies. In other words, the failure of the drug to completely inhibit tumor growth was not caused by regorafenib itself, but by the natural progression of the tumor.

2.Pseudoprogression (Pseudoprogression)

Pseudoprogression mainly refers to the short-term increase in tumor volume on imaging, but it is actually caused by intratumoral inflammatory reaction, necrosis or edema. By resisting angiogenesis and destroying tumor microvessels, regorafenib can cause local tumor necrosis and extravasation, thus appearing as "enlargement" on imaging. In this case, the patient's symptoms may not worsen significantly and tumor markers may stabilize.

3.The emergence of drug resistance mechanisms

After long-term use of regorafenib, tumor cells may acquire drug resistance by activating bypass signals (such as PI3K/AKT, MAPK) or inducing new angiogenesis. This type of drug resistance will weaken the inhibitory effect of drugs on tumors, accelerate the growth rate of some tumors, and thus manifest itself as an increase in tumor size.

4.Imaging errors or measurement differences

Sometimes tumor growth may be due to imaging measurement errors. CT or MRI The different slice positions, contrast agent concentrations or the judgment standards of doctors who read the films may lead to short-term fluctuations in tumor size. Therefore, multiple consecutive imaging evaluations combined with clinical symptoms are needed to determine true disease progression.

3. Response and processing methods

1.Close follow-up and comprehensive evaluation

Patients with tumor enlargement should be comprehensively evaluated based on imaging, tumor markers, and clinical symptoms. If the patient's symptoms are stable, the quality of life does not decline significantly, and the marker levels are stable, false progression or imaging errors need to be considered, and the follow-up interval can be extended and observation can be continued.

2.Adjust drug dosage or medication regimen

If the tumor enlarges and symptoms worsen, the dose of regorafenib may be adjusted under the guidance of a doctor, or combined with other treatments. Commonly used clinical adjustment strategies include intermittent medication, dose reduction, or combination with chemotherapy and immunotherapy to enhance efficacy and reduce toxic side effects.

3.Moving to other targeted or immunotherapies

For patients who have clearly developed drug resistance, other targeted drugs or immunotherapy can be selected based on genetic testing results. For example, for patients with abnormal EGFR, VEGF or MET pathways, corresponding inhibitors can be tried; for immune-sensitive tumors, PD-1/PD-L1 inhibitors can be considered.

4.Symptomatic and supportive treatment

Regardless of whether the anti-tumor regimen is adjusted or not, it is very important to maintain the patient's quality of life. Nutritional support, anti-inflammatory drugs, pain management, and psychological intervention can be used to help patients better tolerate the side effects of treatment.

4. Clinical Tips and Suggestions

Tumor growth while taking regorafenib does not necessarily mean treatment failure. Patients and family members should avoid excessive panic, communicate with the attending doctor in a timely manner, and make a comprehensive judgment based on imaging, symptoms, and marker levels. In actual clinical practice, approximately 10%–15% of patients may experience short-term pseudoprogression, and the development of drug resistance requires genetic testing and multidisciplinary evaluation to develop next steps. With reasonable follow-up, dose adjustment and combination therapy, most patients can still obtain survival benefits from regorafenib.

Overall, in the face of tumor growth, scientific assessment of the condition, compliance with individualized treatment principles and close follow-up are the keys to ensuring that patients receive maximum benefit. At the same time, patients should maintain a good lifestyle and mental state to enhance tolerance to treatment and overall efficacy.

Reference link:https://www.drugs.com